However, anti-hyperglycemics, specifically dipeptidyl peptidase-4 (DPP4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors (only borderline significant, p = 0.06), were taken more often by non-severe COVID-19 patients with cardiovascular conditions or cardiovascular conditions and diabetes (see Supplements, Table S3). The gene discussed is DPP4; the disease is COVID-19.